CHARAH SOLUTIONS INC (CHRA) Fundamental Analysis & Valuation

NYSE:CHRA • US15957P3038

Current stock price

2.17 USD
+0.08 (+3.83%)
Last:

This CHRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CHRA Profitability Analysis

1.1 Basic Checks

  • CHRA had negative earnings in the past year.
  • In the past year CHRA has reported a negative cash flow from operations.
CHRA Yearly Net Income VS EBIT VS OCF VS FCFCHRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

  • The profitability ratios for CHRA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRA Yearly ROA, ROE, ROICCHRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 50 -50 100 -100

1.3 Margins

  • CHRA has a worse Gross Margin (1.79%) than 80.00% of its industry peers.
  • CHRA's Gross Margin has declined in the last couple of years.
  • CHRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.11%
GM growth 5Y-17.64%
CHRA Yearly Profit, Operating, Gross MarginsCHRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 10 -10 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CHRA Health Analysis

2.1 Basic Checks

  • CHRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CHRA has been reduced compared to 1 year ago.
  • Compared to 1 year ago, CHRA has an improved debt to assets ratio.
CHRA Yearly Shares OutstandingCHRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
CHRA Yearly Total Debt VS Total AssetsCHRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of 0.08, we must say that CHRA is in the distress zone and has some risk of bankruptcy.
  • CHRA has a Altman-Z score of 0.08. This is amonst the worse of the industry: CHRA underperforms 80.00% of its industry peers.
  • CHRA has a Debt/Equity ratio of 7.56. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of CHRA (7.56) is worse than 91.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACC6.34%
CHRA Yearly LT Debt VS Equity VS FCFCHRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

  • CHRA has a Current Ratio of 1.14. This is a normal value and indicates that CHRA is financially healthy and should not expect problems in meeting its short term obligations.
  • CHRA has a Current ratio of 1.14. This is in the lower half of the industry: CHRA underperforms 61.25% of its industry peers.
  • A Quick Ratio of 1.09 indicates that CHRA should not have too much problems paying its short term obligations.
  • CHRA has a Quick ratio (1.09) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.09
CHRA Yearly Current Assets VS Current LiabilitesCHRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CHRA Growth Analysis

3.1 Past

  • The earnings per share for CHRA have decreased strongly by -260.00% in the last year.
  • Looking at the last year, CHRA shows a very strong growth in Revenue. The Revenue has grown by 146.66%.
  • The Revenue has been growing slightly by 2.04% on average over the past years.
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-387.5%
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y2.04%
Sales Q2Q%-3.11%

3.2 Future

  • CHRA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -347.79% yearly.
  • CHRA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.09% yearly.
EPS Next Y-436.41%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
EPS Next 5YN/A
Revenue Next Year8.8%
Revenue Next 2Y7.2%
Revenue Next 3Y6.72%
Revenue Next 5Y7.09%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CHRA Yearly Revenue VS EstimatesCHRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CHRA Yearly EPS VS EstimatesCHRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

0

4. CHRA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CHRA. In the last year negative earnings were reported.
  • Also next year CHRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRA Price Earnings VS Forward Price EarningsCHRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRA Per share dataCHRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80

4.3 Compensation for Growth

  • CHRA's earnings are expected to decrease with -347.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. CHRA Dividend Analysis

5.1 Amount

  • CHRA has a Yearly Dividend Yield of 1.26%.
  • The stock price of CHRA dropped by -70.95% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • Compared to an average industry Dividend Yield of 0.86, CHRA pays a bit more dividend than its industry peers.
  • Compared to the average S&P500 Dividend Yield of 1.89, CHRA is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.26%

5.2 History

  • CHRA is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DP0%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
CHRA Yearly Income VS Free CF VS DividendCHRA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M -60M

More info and screens

Find the best dividend stocksShow peers with best dividend

CHRA Fundamentals: All Metrics, Ratios and Statistics

CHARAH SOLUTIONS INC

NYSE:CHRA (4/3/2023, 8:20:29 PM)

2.17

+0.08 (+3.83%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)03-30
Earnings (Next)05-08
Inst Owners88.22%
Inst Owner Change-3.06%
Ins Owners66.98%
Ins Owner Change0%
Market Cap7.33M
Revenue(TTM)318.13M
Net Income(TTM)-40.90M
Analysts48.57
Price Target90.78 (4083.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.26%
Yearly Dividend0.3
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.03%
Min EPS beat(2)-58.73%
Max EPS beat(2)-23.34%
EPS beat(4)0
Avg EPS beat(4)-80.85%
Min EPS beat(4)-130.17%
Max EPS beat(4)-23.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.78%
Min Revenue beat(2)-4.89%
Max Revenue beat(2)-0.67%
Revenue beat(4)1
Avg Revenue beat(4)0.34%
Min Revenue beat(4)-4.89%
Max Revenue beat(4)8.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6257.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-899.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-900.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.7
EYN/A
EPS(NY)-11.31
Fwd EYN/A
FCF(TTM)-24.58
FCFYN/A
OCF(TTM)-23.06
OCFYN/A
SpS94.13
BVpS7.03
TBVpS-25.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.79%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.11%
GM growth 5Y-17.64%
F-Score1
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.09
Altman-Z 0.08
F-Score1
WACC6.34%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)46.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-387.5%
EPS Next Y-436.41%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
EPS Next 5YN/A
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y2.04%
Sales Q2Q%-3.11%
Revenue Next Year8.8%
Revenue Next 2Y7.2%
Revenue Next 3Y6.72%
Revenue Next 5Y7.09%
EBIT growth 1Y-259.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.36%
EBIT Next 3Y26.32%
EBIT Next 5Y22.98%
FCF growth 1Y-5990.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-931.71%
OCF growth 3YN/A
OCF growth 5YN/A

CHARAH SOLUTIONS INC / CHRA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CHARAH SOLUTIONS INC (CHRA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CHRA.


What is the valuation status of CHARAH SOLUTIONS INC (CHRA) stock?

ChartMill assigns a valuation rating of 3 / 10 to CHARAH SOLUTIONS INC (CHRA). This can be considered as Overvalued.


What is the profitability of CHRA stock?

CHARAH SOLUTIONS INC (CHRA) has a profitability rating of 0 / 10.


What is the financial health of CHARAH SOLUTIONS INC (CHRA) stock?

The financial health rating of CHARAH SOLUTIONS INC (CHRA) is 1 / 10.


Can you provide the dividend sustainability for CHRA stock?

The dividend rating of CHARAH SOLUTIONS INC (CHRA) is 1 / 10 and the dividend payout ratio is 0%.